KNSA vs. SUPN, OCUL, ARQT, INVA, PLRX, SMMT, ELAN, KRYS, OGN, and BBIO
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Ocular Therapeutix (OCUL), Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), Krystal Biotech (KRYS), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
Kiniksa Pharmaceuticals has higher earnings, but lower revenue than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kiniksa Pharmaceuticals currently has a consensus price target of $32.00, suggesting a potential upside of 22.51%. Supernus Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 33.33%. Given Supernus Pharmaceuticals' higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.
Supernus Pharmaceuticals has a net margin of -2.60% compared to Kiniksa Pharmaceuticals' net margin of -3.10%. Supernus Pharmaceuticals' return on equity of -1.68% beat Kiniksa Pharmaceuticals' return on equity.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Kiniksa Pharmaceuticals had 27 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 31 mentions for Kiniksa Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.97 beat Kiniksa Pharmaceuticals' score of 0.46 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.
Supernus Pharmaceuticals received 304 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 64.48% of users gave Kiniksa Pharmaceuticals an outperform vote.
Kiniksa Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Summary
Supernus Pharmaceuticals beats Kiniksa Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
